Hoosier Cancer Research Network
@hoosiercancer.bsky.social
43 followers 100 following 30 posts
Hoosier Cancer Research Network conducts innovative cancer research studies with more than 100 academic and community sites across the United States.
Posts Media Videos Starter Packs
hoosiercancer.bsky.social
HCRN welcomes Anna Pavlick, DO, MBA (Weill Cornell), Michael C. Lowe, MD, MA (Emory Winship), and Arkadiusz Z. Dudek, MD, PhD (Mayo Clinic) as co-chairs of the Melanoma Clinical Trial Working Group.

👉 Read more: hoosiercancer.org/collaborativ...

#HCRN #Melanoma #CancerResearch
hoosiercancer.bsky.social
HCRN welcomes Neelima Vidula, MD (Mass General Hospital) & Alison Conlin, MD, MPH (Providence Cancer Institute) as co-chairs of the Breast Cancer Clinical Trial Working Group, joining Carey Anders, MD (Duke Cancer Institute).
Read more: hoosiercancer.org/collaborativ...
hoosiercancer.bsky.social
HCRN’s new report shares insights from a survey of more than 130 researchers across our national network, revealing key trends, challenges, and the impact of IITs on cancer research.
Read more and download the report: hoosiercancer.org/hcrns-report...
hoosiercancer.bsky.social
@medpagetoday.bsky.social published a writeup on HCRN-LUN18-335 (The "RAMOSE" study), which was led by Dr. Xiuning Le of the @mdanderson.bsky.social. This writeup was based on research published in @ascocancer.bsky.social's Journal of Clinical Oncology. Read more www.medpagetoday.com/reading-room...
Add-On Ramucirumab for EGFR-Mutant NSCLC
RAMOSE and RELAY trial results
www.medpagetoday.com
hoosiercancer.bsky.social
Congratulations to HCRN co-founder Dr. Rafat Ansari, who will receive an honorary Doctor of Science degree from @notredame.bsky.social at its 180th University Commencement Ceremony on May 18!

Read more: news.nd.edu/news/notre-d...
hoosiercancer.bsky.social
We are excited to participate in the @ascocancer.bsky.social 2025 Annual Meeting in Chicago! Find us at booth #36117! Learn about our planned activities and featured abstracts at hoosiercancer.org/hcrns-presen... #ASCO2025
hoosiercancer.bsky.social
HCRN is looking for a passionate, dynamic communications and marketing coordinator who will help amplify our mission, reach new audiences, and elevate the impact of our research.

Learn more here: hoosiercancer.org/careers/#ope...
hoosiercancer.bsky.social
Come out to the Indiana Statehouse for Breast Cancer Advocacy Day on Monday! Hoosier Cancer Research Network will be on hand to share how we support researchers working to improve the lives of cancer patients through clinical trials. fox59.com/morning-news...
hoosiercancer.bsky.social
Study Highlight🧑‍⚕️🔬HCRN-GI23-643 is a randomized trial of regorafenib in combination with pembrolizumab or pembrolizumab monotherapy for patients with MSI-H colorectal cancer. Currently open to accrual at @adventhealth.bsky.social Orlando & @upmchillmancc.bsky.social. hoosiercancer.org/all-clinical...
hoosiercancer.bsky.social
HCRN launched an updated website with new features and a modernized design, developed in collaboration with THE PLAID AGENCY. Visit our new website and read more about it here: hoosiercancer.org/hcrn-launche...
hoosiercancer.bsky.social
Researchers participating in the HCRN-GU16-260 study have published a correlative analysis in Cancer Discovery. Congratulations to all co-authors and study teams whose hard work led to this publication! Read more: hoosiercancer.org/correlative-...
hoosiercancer.bsky.social
A HCRN non-small cell lung cancer study (RAMOSE trial) was published and featured in the February 1, 2025 issue of the Journal of Clinical Oncology. Congratulations to all co-authors and study teams whose hard work led to this publication!
Read more: hoosiercancer.org/hcrn-non-sma...
hoosiercancer.bsky.social
Congratulations to Dr. Deepak Kilari of @froedtert.bsky.social and all co-authors on presenting the ABATE study, HCRN-GU18-343! #GU25
Reposted by Hoosier Cancer Research Network
crisbergerot.bsky.social
Exciting findings from the HCRN GU18-343 ABATE study: A phase 2 trial evaluating cabozantinib + atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer! 🚀🔬 Don’t miss the insights at @ascocancer.bsky.social #GU25
hoosiercancer.bsky.social
Thank you to everyone who attended our GU Working Group meeting. We appreciate your time and contributions to the discussion! #GU25
hoosiercancer.bsky.social
We are happy to announce our arrival on Bluesky! In addition to X, Facebook, and LinkedIn, you can now connect with us on here at @hoosiercancer.bsky.social. Follow us and join the growing conversation!
hoosiercancer.bsky.social
Thank you to all investigators who joined the HCRN GI Clinical Trial Working Group meeting this morning. Great discussion on new concepts and current studies. #GI25 #OncSky #MedSky
hoosiercancer.bsky.social
HCRN-GI23-643 will be presented as a Trials in Progress poster at the @ascocancer.bsky.social Gastrointestinal Cancers Symposium 2025 in San Francisco. This study is led by Ibrahim Sahin, MD, of UPMC Hillman Cancer Center.

Read more: hoosiercancer.org/hcrn-gi23-64...
hoosiercancer.bsky.social
Congrats to Rana Mckay of UC San Diego Health Moores Cancer Center on being elected to the @ascocancer.bsky.social Nominating Committee! She serves as a co-chair of the our GU Clinical Trial Working Group & is a sponsor-investigator of multiple HCRN studies.

connection.asco.org/do/dr-elizab...
hoosiercancer.bsky.social
The NePtune study tests if combining olaparib + hormone therapy before surgery can reduce cancer & recurrence in prostate cancer patients with DNA repair mutations. It aims to improve outcomes for men with aggressive localized prostate cancer.
Learn more: www.facingourrisk.org/blog/what-is...